Small molecule compound targeting SRSF6 protein and preparation method and use thereof
By targeting small-molecule compounds of SRSF6 protein inhibit abnormal alternative splicing events, the tumor occurrence and development problems caused by SRSF6 protein were solved, significantly inhibited the growth of colorectal cancer cells, and showed good pharmacokinetic characteristics in the body. New drug candidates are provided for the treatment of colorectal cancer.
Patent Information
- Application Number
- CN202111293452.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-11-03
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-11-03
AI Technical Summary
The prior art is difficult to effectively inhibit abnormal alternative splicing events caused by SRSF6 protein, thereby promoting the occurrence and development of tumors, especially in colorectal cancer.
A small molecule compound targeting SRSF6 protein was developed to bind to SRSF6 protein through specific chemical structures to inhibit abnormal alternative splicing events in its highly expressed cells. The preparation method includes 5-acetyl-2,8-dihydroxyl Quinoline reacts with R1X, brominates, stereoselective reduction and intramolecular cycling, and reacts with nucleophilic reagents to form the target compound.
This compound significantly inhibited the abnormal function of SRSF6 protein, reduced abnormal alternative splicing events, showed significant inhibitory effects on colorectal cancer cells, and had good pharmacokinetic data in the body, for the chemotherapy of colorectal cancer. Potential drug molecules are provided.
Smart Images

Figure CN115677577B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and in particular to a small molecule compound targeting SRSF6 protein, a preparation method and use thereof. Background Art
[0002] Studies have shown that abnormal alternative splicing (AS) is common in the occurrence and development of tumors, and most tumor-related genes have abnormal physiological functions due to abnormal splicing. SR (serine / arginine-rich) proteins are a class of serine / arginine-rich splicing factors. There are 12 SRSF members in its protein family. Their common structure includes an RNA recognition motif (RRM domain) located at the N-terminus and an arginine / serine-rich domain (RS domain) containing highly phosphorylated serine / arginine at the C-terminus. SR proteins specifically bind to pre-RNA through the RRM domain to determine the splicing site; the RS domain recruits other splicing factors to participate in RNA splicing. The dysregulated expression of SR proteins will lead to abnormalities in various splicing processes, thereby promoting the occurrence of malignant tumors. SRSF6 (serine / arginine-rich splicing factor 6) protein is a member of the SR protein family. Studies have shown that its expression is upregulated in cancers such as colorectal cancer and lung cancer. SRSF6 can bind to the motif of exon 23 (exon23) of the cell adhesion factor ZO-1, activate the splicing of ZO-1exon23, lead to abnormal alternative splicing, and then promote the occurrence and development of colorectal cancer.
[0003] Colorectal cancer (CRC) is a common digestive tract malignant tumor formed on the inner wall of the colon or rectum. It is one of the malignant tumors that poses a great threat to human survival and health in the world today, and ranks third in the spectrum of cancer deaths in developed Western countries. With the changes in residents' lifestyles and dietary structures, the incidence of colorectal cancer in my country has shown a clear upward trend and has ranked second among new cancers in my country. The cause of colorectal cancer is complex and can occur in any part of the colon or rectum. Indacaterol is a drug used for adult patients with chronic obstructive pulmonary disease (COPD), and studies have shown that it can be used to treat tumors, especially colorectal tumors; it achieves the effect of inhibiting cell proliferation, migration, and invasion by regulating alternative splicing in cells. Summary of the invention
[0004] Purpose of the invention: The present invention provides a small molecule compound targeting SRSF6 protein and its preparation method and use. The molecule can selectively inhibit abnormal cells with high expression of SRSF6, thereby reducing the occurrence of abnormal alternative splicing events, inhibiting the occurrence and development of tumors, especially colorectal tumors, and can be used as a candidate new drug for anti-colorectal cancer.
[0005] Technical solution: The present invention provides a compound as shown in the general formula (I):
[0006]
[0007] in:
[0008] R 1 is selected from substituted or unsubstituted C 1 -C 3 Straight chain alkyl, substituted or unsubstituted C 1 -C 3 Alkenyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 6 -C 10 Aralkyl, C 6 -C 10 Halogenated aralkyl or C 6 -C 10 A heteroaromatic ring group, wherein the heteroatoms of the heteroaromatic group are each independently selected from N, O, and S;
[0009] R 2 Selected from C 1 -C 3 Alkoxy, substituted amino, C 1 -C 8 Fatty amine, saturated or unsaturated substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 6 -C 10 Heteroaryl, halogenated aromatic carbocyclic amine or substituted or unsubstituted 5-7 membered heterocyclic group, wherein the heteroatoms in the heteroaryl or heterocyclic group are independently selected from N, O, S, and the halogenated halogen atom refers to fluorine, chlorine, bromine or iodine; the substituted amino group is substituted by 1-3 of the following substituents: C 1 -C 4 Alkyl, 5,6-diethylindanyl, substituted or unsubstituted phenyl, indanyl, indolyl, piperidinyl substituted with methanesulfonyl, benzothiazolyl, benzimidazolyl;
[0010] X is selected from hydroxy or halogen, wherein the halogen is selected from fluorine, chlorine, bromine and iodine;
[0011] The chiral center* is in the S or R configuration.
[0012] Preferably, R 1 is selected from methyl, allyl, substituted or unsubstituted benzyl, substituted or unsubstituted pyridyl or triazole; the substituted or unsubstituted benzyl is independently substituted by 1 to 3 groups: halogen or C 1 -C 3 alkyl;
[0013] R 2 Selected from R 2 is selected from methoxy, 5,6-diethyl-2,3-dihydro-1H-indene-2-amino, 2-aminoindanyl, anilino, bromoanilino, heteroarylamino, C 1 -C 4 Aliphatic amine, morpholinyl, piperidinyl, pyrrolyl, substituted or unsubstituted piperazinyl, substituted or unsubstituted homopiperazinyl, indolyl, 2,3-dihydroindanyl, wherein the substituted or unsubstituted piperazinyl or substituted or unsubstituted homopiperazinyl is substituted by 1 to 3 of the following independent substituents: C 1 -C 4 alkyl, substituted or unsubstituted phenyl or substituted or unsubstituted benzyl, wherein the phenyl or benzyl is substituted by a halogen or C 1 -C 3 alkyl.
[0014] Preferably, R 1 is selected from benzyl, 3-substituted benzyl, 4-substituted benzyl or polysubstituted benzyl, wherein the substituent of the benzyl is methyl or halogen;
[0015] R 2 Selected from 5,6-diethyl-2,3-dihydro-1H-indene-2-amine, N-phenylpiperazinyl, N-phenylhomopiperazinyl, bromoanilino, 2,3-dihydroindole or 2,3-dihydroindenyl; the N-phenylpiperazinyl is selected from: benzyl substituted piperazinyl, methylbenzyl substituted piperazinyl or benzyl bromide substituted piperazinyl; the N-phenylhomopiperazinyl is selected from: benzyl substituted homopiperazinyl, methylbenzyl substituted homopiperazinyl or benzyl bromide substituted homopiperazinyl.
[0016] Preferably, the multi-substituted benzyl group is a 3,5-halogenated benzyl group, a 3,4-halogenated benzyl group or a perhalogenated benzyl group.
[0017] Preferably, the R 1 Selected from benzyl, 4-methylbenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 3,5-difluorobenzyl, 3,4-difluorobenzyl, perfluorobenzyl;
[0018] R 2Selected from 5,6-diethyl-2,3-dihydro-1H-indene-2-amino, 2-bromoanilino, 2,3-dihydroindolinyl, 2,3-dihydroindenyl, benzyl substituted piperazinyl, 4-methylbenzyl substituted piperazinyl, 4-bromobenzyl substituted piperazinyl, benzyl substituted homopiperazinyl, 4-methylbenzyl substituted homopiperazinyl.
[0019] In some embodiments, the compound is preferably selected from the following compounds:
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028] The second aspect of the invention provides a method for preparing the above compound, comprising the following steps:
[0029] 5-Acetyl-2,8-dihydroxyquinoline and R 1 X is then brominated to obtain compound II, and the brominating agent selected for bromination can be selected from bromine water, N-bromosuccinimide or tetrabutylammonium tribromide; compound II is stereoselectively reduced to compound III by (R) / (S)-2-methyl-CBS-oxazolidinone coordinated with borane, and compound III is intramolecularly cyclized under alkaline conditions and then reacts with a nucleophilic reagent R 2 H reaction to obtain the target compound I, the synthesis route is as follows:
[0030]
[0031] Or compound I is further halogenated to obtain compound I':
[0032]
[0033] Preferably, in the reaction of preparing compound III from compound II, the solvent is selected from one or more of anhydrous acetonitrile, anhydrous dichloromethane, chloroform, anhydrous tetrahydrofuran, anhydrous N,N′-dimethylformamide, and dimethyl sulfoxide; according to the chirality requirements, (R) or (S)-CBS chiral catalysts are selected respectively, and borane is used for asymmetric reduction; the reaction temperature is -20°C to 25°C.
[0034] In the reaction of preparing compound IV from compound III: the solvent is selected from one or more of acetonitrile, dichloromethane, chloroform, acetone, tetrahydrofuran, methanol, N,N-dimethylformamide, dimethyl sulfoxide or dioxane; the base is selected from potassium carbonate, sodium carbonate, sodium bicarbonate, sodium hydroxide, potassium hydroxide or triethylamine; the reaction temperature is from 25°C to heating reflux;
[0035] In the reaction of preparing compound I from compound IV: the solvent is selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, n-butanol or diethylene glycol dimethyl ether; the reaction temperature is 60° C. to 150° C.;
[0036] In the reaction of preparing compound I' from compound I: the solvent is selected from one or more of acetonitrile, dichloromethane, chloroform or tetrahydrofuran, and reacts with a halogenating agent under the protection of an inert gas, and the reaction temperature is -20°C to 0°C.
[0037] Preferably,
[0038] More preferably, in the method for preparing the compound, in the reaction of preparing compound III from compound II, the solvent is anhydrous tetrahydrofuran, the catalyst is (R)-2-methyl-CBS-oxazoloborane or (S)-2-methyl-CBS-oxazoloborane as needed, and the reaction temperature is -20°C to 0°C;
[0039] In the reaction of preparing compound IV from compound III: the solvent is acetone, the base is potassium carbonate or triethylamine, and the reaction temperature is 55°C to 65°C.
[0040] In the reaction of preparing compound I from compound IV: the solvent is selected as n-butanol, and the reaction temperature is 110°C to 120°C.
[0041] These compounds can be purified according to conventional separation techniques.
[0042] Preferably, in the reaction of preparing compound I' from compound I: the solvent is dichloromethane, the reaction is carried out under nitrogen protection, and the reaction temperature is -20°C to 0°C.
[0043] The third aspect of the present invention provides the use of the above compound in the preparation of a drug for treating diseases related to malignant tumors.
[0044] Preferably, the malignant tumor-related diseases are various tumors mediated by overexpression of SRSF6 protein, including colorectal tumors (colorectal tumors mediated by overexpression of SRSF6 protein).
[0045] In some embodiments of the present invention, indacaterol and its intermediates were used as positive controls, and in vitro cell experiments were performed to demonstrate that the compounds of the present invention had significant inhibitory effects on colorectal cancer cell lines such as RKO, HT-29, and SW620.
[0046] In some embodiments of the present invention, SPR affinity experiments and protein thermal shift experiments have been performed to prove that compound I 1 It has a good binding effect with SRSF6 protein.
[0047] In some embodiments of the present invention, the pharmacokinetic experiments in rats have shown that compound I 1 ,I 5 ,I 7 Has good in vivo pharmacokinetic data.
[0048] Beneficial effects: The compounds of the present invention are used for targeted treatment of colorectal tumors and other tumors with high expression of SRSF6, providing potential drug molecules for the chemotherapy of colorectal cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 The representative compound I of the present invention 1 Verification of binding to SRSF6 protein fragments;
[0050] Figure 2 The representative compound I of the present invention is 1 (LYW2), I 5 (LYW3), I 7 Blood drug concentration-time curves of (LYW4) and the reference indacaterol intermediate (LYW1) in SPF rats after intravenous injection and oral administration (n=3). DETAILED DESCRIPTION
[0051] In order to further illustrate the present invention, a series of examples are given below. These examples are purely illustrative and are only used to specifically describe the present invention, and should not be understood as limiting the present invention.
[0052] 1. Compound Synthesis
[0053] Example 1: Preparation of (S)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-((4-fluorobenzyl)oxy)quinolin-2(1H)-one (I 1 )
[0054]
[0055] 1.1 Intermediate II 1 Synthesis
[0056] After adding 5-acetyl-2,8-dihydroxyquinoline (1 g, 4.92 mmol) and anhydrous potassium carbonate (816 mg, 5.91 mmol) into the reaction bottle, add acetone (20 mL) and heat to reflux. Under reflux conditions, add 4-fluorobenzyl bromide (727 uL, 5.91 mmol) dropwise. After sufficient stirring, collect 1.3 g of filter cake.
[0057] After adding the filter cake (1.3 g, 4.18 mmol) into the reaction flask, anhydrous THF (26 mL) and anhydrous methanol (10 mL) were added and the temperature was raised to 40°C and stirred thoroughly. Then, tetrabutylammonium tribromide (2.82 g, 5.85 mmol) was slowly added in batches to brominate the terminal primary carbon to obtain the representative intermediate 5-(2-bromoacetyl)-8-4-(fluorobenzyl)oxyquinoline-2(1H)-one (Compound II 1 ).
[0058] 1 H NMR (300 MHz, DMSO-d 6 )δ11.14(s,1H),8.50(d,J=10.1Hz,1H),7.88(d,J=8.6Hz,1H),7.71–7.65(m,2H),7.32(d,J=8.6Hz,1 H),7.25(d,J=8.9Hz,2H),6.68(d,J=10.0Hz,1H),5.41(s,2H),4.94(s,2H).MS(ESI)m / z=390.0[M+H] + (C 18 H 13 BrFNO 3 ).
[0059] 1.2 Intermediate III 1 Synthesis
[0060] Under nitrogen protection, compound II 1(500mg, 1.27mmol) was added to a 100mL double-necked reaction bottle, anhydrous THF (15mL) and a catalytic amount of (S)-2-methyl-CBS-oxazolidinone (1M, 128μL, 0.13mmol) were added, and the mixture was placed in a -10℃ cold trap and stirred thoroughly. After 10min, borane-tetrahydrofuran complex (1M, 1.54mL, 1.54mmol) was measured and slowly dripped into the reaction system within half an hour. Stirring was continued at this temperature for 15min. The reaction was completed by TLC monitoring, and methanol (5mL) was used to quench the reaction. After removing the solvent by concentrating under reduced pressure, 1M hydrochloric acid solution (50mL) was added to the bottle, stirred at room temperature overnight, filtered, and the filter cake was collected and dried in vacuo to obtain white solid III. 1 455 mg, yield: 90.53%.
[0061] 1 H NMR (400 MHz, DMSO-d 6 )δ10.79(s,1H),8.19(d,J=10.0Hz,1H),7.69–7.62(m,2H),7.27–7.17(m,4H),6.57(d,J=9.9Hz,1H),5.97(s, 1H),5.28(s,2H),5.26–5.18(m,1H),3.69(dd,J=10.4,4.8Hz,1H),3.65–3.60(m,1H).MS(ESI)m / z=392.0[M+H] + (C 18 H 15 BrFNO 3 ).
[0062] 1.3 Intermediate IV 1 Synthesis
[0063] Compound III 1 (400 mg, 1.02 mmol) was added to a 100 mL single-mouth reaction bottle, and redistilled acetone (40 mL) and anhydrous potassium carbonate (211 mg, 1.53 mmol) were added, heated to reflux, and stirred thoroughly. After 4 h, the reaction was completed by TLC monitoring, filtered, the filter cake was washed with acetone, and the combined filtrate was collected. After the filtrate was concentrated under reduced pressure to remove the solvent, ethyl acetate was added for recrystallization to obtain a light yellow solid IV 1 272 mg, yield: 85.67%.
[0064] 1H NMR(400MHz,Chloroform-d)δ9.23(s,1H),8.11(d,J=9.8Hz,1H),7.47–7.39(m,2H),7.16–7.08(m,3H),7.02(d,J=8.3Hz,1H),6.75 (d,J=9.8Hz,1H),5.16(s,2H),4.26–4.21(m,1H),3.23(dd,J=5.6,4.0Hz,1H),2.80(dd,J=5.6,2.6Hz,1H).MS(ESI)m / z=312.1[M+H] + (C 18 H 14 FNO 3 ).
[0065] 1.4 Target product I 1 Synthesis
[0066] Compound IV 1 (250mg, 0.80mmol) and 5,6-diethyl-2,3-dihydro-1H-inden-2-amine (167mg, 0.88mmol) were added to a single-mouth reaction bottle, 15mL of n-butanol was added to dissolve it, and the temperature was raised to 110°C. At this temperature, it was fully stirred for 5h. The reaction was monitored by TLC to complete. The reaction solution was concentrated and purified by silica gel column chromatography to obtain the target product I 1 81 mg, yield: 20.15%.
[0067] 1 H NMR (400 MHz, DMSO-d 6 )δ10.81(s,1H),8.28(d,J=10.0Hz,1H),7.69–7.63(m,2H),7.27–7.18(m,4H),6.98(s,2H),6.58(d,J=9.9Hz,1H),5.34(d,J=8.9Hz,1H),3.82 (p,J=7.4Hz,1H),3.12(ddd,J=15.6,11.7,7.6Hz,2H),3.02–2.82(m,4H),2.57(d,J=7.5Hz,2H),2.53(d,J=7.4Hz,2H),1.12(t,J=7.5Hz,6H). 13 C NMR (101 MHz, DMSO-d 6)δ161.37,143.93,140.07,138.41,138.36,136.91,132.02,130.67,130.59,129.91,124.64,122.81,11 9.88,115.69,115.48,112.63,69.48,67.19,58.75,54.18,37.28,25.33,16.10.MS(ESI)m / z=501.3[M+H] + (C 31 H 33 FN 2 O 3 ).
[0068] Example 2: Preparation of (R)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-((4-fluorobenzyl)oxy)quinolin-2(1H)-one (I 2 )
[0069]
[0070] (1) Intermediate III 2 Synthesis
[0071] When preparing compound III from compound II, the catalyst in the reaction is changed to (R)-2-methyl-CBS-oxazaborolidine to obtain intermediate III in Example 1 1 Enantiomer III 2 , the steps are as follows:
[0072] Under nitrogen protection, compound II 1 (500mg, 1.27mmol) was added to a 100mL double-necked reaction bottle, anhydrous THF (15mL) and a catalytic amount of (R)-2-methyl-CBS-oxazolidinone (1M, 128μL, 0.13mmol) were added, and the mixture was placed in a -10℃ cold trap and stirred thoroughly. After 10min, borane-tetrahydrofuran complex (1M, 1.54mL, 1.54mmol) was measured and slowly dripped into the reaction system within half an hour. Stirring was continued at this temperature for 15min. The reaction was completed by TLC monitoring, and the reaction was quenched with methanol (5mL). After removing the solvent by vacuum concentration, 1M hydrochloric acid solution (50mL) was added to the bottle, and the mixture was stirred at room temperature overnight and then filtered. The filter cake was collected and dried in vacuo to obtain white solid III. 2 461 mg, yield: 91.73%.
[0073] 1 H NMR (400 MHz, DMSO-d 6)δ10.78(s,1H),8.19(d,J=10.0Hz,1H),7.67–7.63(m,2H),7.24–7.19(m,4H),6.57(d,J=9.9Hz,1H),5.97(d,J=4.7Hz,1H),5 .29(s,2H),5.23(dt,J=7.3,4.8Hz,1H),3.69(dd,J=10.4,4.8Hz,1H),3.62(dd,J=10.4,7.2Hz,1H).MS(ESI)m / z=392.0[M+H] + (C 18 H 15 BrFNO 3 ).
[0074] (2) Target product I 2 Synthesis
[0075] The obtained intermediate III 2 Referring to the method of step 1.3 in Example 1, intermediate IV was synthesized. 2 Referring to the method of step 1.4 in Example 1, intermediate IV 2 (300 mg, 0.96 mmol) and 5,6-diethyl-2,3-dihydro-1H-indene-2-amine (200 mg, 1.06 mmol) were reacted and purified by silica gel column chromatography to obtain the target product I 2 103 mg, yield: 21.35%.
[0076] 1 H NMR (400 MHz, DMSO-d 6 )δ10.85(s,1H),8.32(t,J=11.1Hz,1H),7.65(t,J=6.9Hz,2H),7.33–7.12(m,4H),6.96(d,J=14.3Hz,2H),6.59(t,J=7.8Hz,1H) ,5.48(s,1H),5.29(s,2H),4.04–3.82(m,2H),3.06(ddd,J=35.7,20.1,9.8Hz,6H),2.54(d,J=7.4Hz,3H),1.10(t,J=6.7Hz,6H). 13 C NMR (101 MHz, DMSO-d 6)δ161.41,144.09,140.30,137.78,133.26,131.28,130.66,130.58,129.91,124.56,122.96,119 .93,117.08,115.69,115.48,112.60,69.46,58.42,36.11,25.31,16.04.MS(ESI)m / z=501.3[M+H] + (C 31 H 33 FN 2 O 3 ).
[0077] Example 3: Preparation of (S)-8-((4-fluorobenzyl)oxy)-5-(1-hydroxy-2-methoxyethyl)quinolin-2(1H)-one (I 3 )
[0078]
[0079] Referring to the method of step 1.4 in Example 1, intermediate IV 1 (200 mg) and anhydrous methanol (2 mL) were reacted and purified by silica gel column chromatography to obtain the target product I 3 128 mg, yield: 58.03%.
[0080] 1 H NMR (400 MHz, DMSO-d 6 )δ10.70(s,1H),8.21(d,J=9.9Hz,1H),7.66(dd,J=8.5,5.7Hz,2H),7.26–7.19(m,3H),7.06(d,J=8.3Hz,1H),6.56(d,J=9.9 Hz,1H),5.27(s,2H),4.89(t,J=5.9Hz,1H),4.65(dd,J=7.0,4.6Hz,1H),3.65–3.57(m,1H),3.50–3.42(m,1H),3.19(s,3H). 13 C NMR (101 MHz, DMSO-d 6 )δ161.35,144.05,137.22,133.34,133.31,130.69,130.60,129.95,128.99,122.55,121. 02,118.22,115.70,115.49,112.46,82.59,69.56,66.08,56.88.MS(ESI)m / z=344.1[M+H] + (C 19H 18 FNO 4 ).
[0081] Example 4: Preparation of (S)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-((4-methylbenzyl)oxy)quinolin-2(1H)-one (I 4 )
[0082]
[0083] Substituting 4-methylbenzyl bromide for 4-fluorobenzyl bromide in Example 1, and referring to the method and reaction conditions in Example 1, the target product I can be obtained. 4 .
[0084] 1 H NMR(300MHz,Chloroform-d)δ9.38(s,1H),8.48(s,1H),8.08(d,J=10.0Hz,1 H),7.34–7.28(m,4H),7.21(d,J=7.7Hz,2H),6.96(d,J=5.1Hz,2H),6.57(d,J =9.6Hz,1H),5.62(d,J=9.5Hz,1H),5.12(d,J=5.1Hz,2H),3.97–3.83(m,1H), 3.29–3.05(m,6H),2.59(q,J=7.5Hz,4H),2.39(s,3H),1.18(t,J=7.5Hz,6H). 13 C NMR(75MHz,Chloroform-d)δ169.64,161.33,141.06,138.51,136.59,136.17,132.46,129.50,128.90,128.01,124. 41,122.64,119.96,111.04,77.26,70.89,66.23,58.97,53.74,36.54,25.45,21.28,15.48.MS(ESI)m / z=497.3[M+H] + (C 32 H 36 N 2 O 3 )
[0085] Example 5: Preparation of (R)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-((4-methylbenzyl)oxy)quinolin-2(1H)-one (I 5 / LYW3)
[0086]
[0087] Substituting 4-methylbenzyl bromide for 4-fluorobenzyl bromide in Example 1, and referring to the method and reaction conditions in Example 2, the target product I can be obtained. 5 .
[0088] 1 H NMR (300MHz, DMSO-d6) δ8.20(d,J=10.0Hz,1H),7.45(d,J=8.0Hz,2H),7.18(d,J=7.9Hz,4H),6.93(d,J=2.1Hz,2H),6.54(d,J=9.9Hz,1H),5.24(s,2 H),5.04(t,J=6.1Hz,1H),3.54-3.49(m,1H),2.98(m,2H),2.73(d,J=6.4H z,2H),2.64-2.57(m,2H),2.53(m,4H),2.28(s,3H),1.12(t,J=7.5Hz,6H). 13 C NMR (75MHz, DMSO) δ161.29,143.59,139.73,139.67,139.44,137.57,134.12,133.47,129.78,129.36,128.37,124.6 3,122.31,119.84,117.26,112.59,70.12,69.41,59.67,56.03,40.26,25.34,21.24,16.15.MS(ESI)m / z=497.3[M+H] + (C 32 H 36 N 2 O 3 ).
[0089] Example 6: Preparation of (S)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-((3-fluorobenzyl)oxy)quinolin-2(1H)-one (I 6 )
[0090]
[0091] Substituting 3-fluorobenzyl bromide for 4-fluorobenzyl bromide in Example 1, and referring to the method and reaction conditions in Example 1, the target product I can be obtained. 6 .
[0092] 1 H NMR (400 MHz, DMSO-d 6)δ10.82(s,1H),8.32(s,1H),8.24(d,J=9.9Hz,1H),7.54(d,J=8.7Hz,1H),7.42(t,J=5.6Hz,2H) ,7.23(s,2H),7.14(ddt,J=9.0,6.2,2.7Hz,1H),6.97(s,2H),6.59(d,J=9.9Hz,1H),5.32(s,2H), 5.25(dd,J=9.2,3.6Hz,1H),3.77(p,J=7.3Hz,1H),3.09(ddd,J=15.7,10.8,7.5Hz,2H),2.95(td, J=13.7,12.9,6.2Hz,2H),2.83(dt,J=16.2,8.0Hz,2H),2.59–2.52(m,4H),1.12(t,J=7.5Hz,6H). 13 C NMR (101 MHz, DMSO-d 6 )δ165.46,161.43,143.83,139.95,138.66,138.62,136.96,132.48,130.76,130.68,129.87,124.64,124.62,124.14,124.11,122.7 5,119.91,117.22,115.17,114.98,114.95,112.54,69.43,67.61,58.88,54.45,37.75,37.68,25.33,16.09.MS(ESI)m / z=501.3[M+H] + (C 31 H 33 FN 2 O 3 ).
[0093] Example 7: Preparation of (R)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-((3-fluorobenzyl)oxy)quinolin-2(1H)-one (I 7 / LYW4)
[0094]
[0095] Substituting 3-fluorobenzyl bromide for 4-fluorobenzyl bromide in Example 1, and referring to the method and reaction conditions in Example 2, the target product I can be obtained. 7 .
[0096] 1 H NMR (400 MHz, DMSO-d 6)δ10.77(s,1H),8.21(d,J=10.0Hz,1H),7.57–7.52(m,1H),7.45–7.39(m,2H),7.19(d,J=2.0H z,2H),7.14(ddd,J=9.0,6.6,2.6Hz,1H),6.93(d,J=3.5Hz,2H),6.56(d,J=9.9Hz,1H),5.42(s ,1H),5.31(s,2H),5.05(t,J=6.1Hz,1H),3.52(q,J=6.6Hz,1H),2.98(ddd,J=15.5,11.6,6.9H z,2H),2.77–2.72(m,2H),2.60(t,J=5.6Hz,1H),2.54(t,J=7.5Hz,5H),1.12(t,J=7.5Hz,6H). 13 C NMR (101 MHz, DMSO-d 6 )δ161.46,143.52,139.80,139.75,139.42,137.29,133.84,130.75,130.66,129.77,124.68,124.64,124.12,124.09 ,122.40,119.86,117.37,115.17,114.95,112.48,69.52,69.43,59.72,56.13,25.34,16.14.MS(ESI)m / z=501.3[M+H] + (C 31 H 33 FN 2 O 3 ).
[0097] Example 8: Preparation of (R)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-((2-fluorobenzyl)oxy)quinolin-2(1H)-one (I 8 )
[0098]
[0099] Substituting 2-fluorobenzyl bromide for 4-fluorobenzyl bromide in Example 1, and referring to the method and reaction conditions in Example 2, the target product I can be obtained. 8 .
[0100] 1 H NMR (300 MHz, DMSO-d 6)δ10.62(s,1H),8.42(d,J=10.0Hz,1H),7.72(t,J=7.6Hz,1H),7.46–7.3 4(m,2H),7.26(dd,J=14.3,7.7Hz,3H),6.91(d,J=5.8Hz,2H),6.59(d,J= 9.9Hz,1H),5.31(s,2H),5.06(s,1H),4.48(s,1H),3.68–3.49(m,4H),2. 86(dp,J=20.5,6.9Hz,3H), 2.54(d,J=7.9Hz,4H), 1.09(t,J=7.5Hz,6H). 13 C NMR (75 MHz, DMSO-d 6 )δ161.33,143.86,139.67,136.95,131.34,131.29,130.88,130.77,129.80,124.97,124.92,124.71,124.48,123. 98,123.79,122.57,121.50,118.68,115.88,115.60,112.59,64.80,57.65,25.30,16.08.MS(ESI)m / z=501.3[M+H] + (C 31 H 33 FN 2 O 3 ).
[0101] Example 9: Preparation of (S)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-((3,5-difluorobenzyl)oxy)quinolin-2(1H)-one (I 9 )
[0102]
[0103] Substituting 3,5-difluorobenzyl bromide for 4-fluorobenzyl bromide in Example 1, and referring to the method and reaction conditions in Example 1, the target product I can be obtained. 9 .
[0104] 1 H NMR (400 MHz, DMSO-d 6)δ11.01(s,1H),8.34–8.30(m,1H),8.24(d,J=9.7Hz,1H),7.44(d,J=6.8Hz,2H),7.2 3(s,2H),7.17(dt,J=9.1,2.4Hz,1H),6.97(s,2H),6.59(d,J=9.9Hz,1H),5.31(s,2H ),5.22(s,1H),3.77–3.67(m,1H),3.07(ddd,J=15.3,11.2,7.3Hz,2H),2.89(p,J=11 .5Hz,2H),2.78(dt,J=15.2,7.0Hz,2H),2.55(t,J=7.5Hz,4H),1.12(t,J=7.5Hz,6H). 13 C NMR (101 MHz, DMSO-d 6 )δ161.52,143.64,139.84,138.85,136.98,129.80,124.64,122.76,119.89,117.28,112.45 ,111.39,111.14,103.63,68.92,67.92,59.04,54.74,25.33,16.12.MS(ESI)m / z=519.3[M+H] + (C 31 H 32 F 2 N 2 O 3 ).
[0105] Example 10: Preparation of (S)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-((3,4-difluorobenzyl)oxy)quinolin-2(1H)-one (I 10 )
[0106]
[0107] Substituting 3,4-difluorobenzyl bromide for 4-fluorobenzyl bromide in Example 1, and referring to the method and reaction conditions in Example 1, the target product I can be obtained. 10 .
[0108] 1 H NMR (400 MHz, DMSO-d 6)δ10.87(s,1H),8.23(d,J=10.0Hz,1H),7.85–7.79(m,1H),7.44(q,J=4.5Hz,2H),7.27– 7.19(m,2H),6.95(d,J=2.0Hz,2H),6.57(d,J=9.9Hz,1H),5.27(s,2H),5.17(dd,J=8.1,4 .4Hz,1H),3.64(q,J=7.0Hz,1H),3.04(ddd,J=15.3,11.3,7.2Hz,2H),2.85(q,J=7.2,6.2 Hz,2H),2.72(ddd,J=15.7,6.9,3.8Hz,2H),2.55(t,J=7.5Hz,4H),1.12(t,J=7.5Hz,6H). 13 C NMR (101 MHz, DMSO-d 6 )δ161.49,143.62,139.71,139.16,139.12,137.09,134.91,133.15,125.20,124.67,124.63,122.62,119.8 6,117.79,117.62,112.50,68.94,68.40,59.23,55.21,38.64,38.52,25.33,16.13.MS(ESI)m / z=519.3[M+H] + (C 31 H 32 F 2 N 2 O 3 ).
[0109] Example 11: Preparation of (S)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-((perfluorobenzyl)oxy)quinolin-2(1H)-one (I 11 )
[0110]
[0111] Substituting perfluorobenzyl bromide for 4-fluorobenzyl bromide in Example 1, and referring to the method and reaction conditions in Example 1, the target product I can be obtained. 11 .
[0112] 1 H NMR (400 MHz, DMSO-d 6)δ10.84(s,1H),8.21(d,J=10.0Hz,1H),7.32(d,J=8.4Hz,1H),7.25(d,J=8.4 Hz,1H),6.95(d,J=3.8Hz,2H),6.54(d,J=9.9Hz,1H),5.28(s,2H),5.08(t,J=6 .1Hz,1H),3.54(q,J=6.7Hz,1H),2.99(ddd,J=15.4,11.7,7.0Hz,2H),2.76(d, J=6.2Hz,2H),2.65–2.57(m,2H),2.54(d,J=7.5Hz,4H),1.12(t,J=7.5Hz,6H). 13 CNMR (101MHz, DMSO-d 6 )δ161.54,143.71,139.77,139.45,137.19,134.41,129.52,124.71,124.66,122.57,11 9.87,117.31,112.21,69.44,59.71,58.48,56.13,25.34,16.16.(ESI)m / z=573.3[M+H] + (C 31 H 29 F 5 N 2 O 3 ).
[0113] Example 12: Preparation of (R)-8-(Benzyloxy)-5-(2-(4-butylpiperazin-1-yl)-1-hydroxyethyl)quinolin-2(1H)-one (I 12 )
[0114]
[0115] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and 1-butylpiperazine (116 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 82 mg of the target product in a yield of 27.61%.
[0116] 1 H NMR (300 MHz, DMSO-d 6)δ10.64(s,1H),8.18(d,J=9.9Hz,1H),7.63–7.51(m,2H),7.36(dt,J=14.4,7.0Hz, 3H),7.23–7.11(m,2H),6.54(d,J=9.9Hz,1H),5.29(s,2H),5.16(d,J=3.9Hz,1H),2 .63–2.46(m,4H),2.44–2.30(m,4H),2.21(t,J=7.2Hz,4H),1.37(dq,J=14.6,6.8Hz ,2H),1.22(dq,J=19.9,7.2Hz,2H),0.86(t,J=7.1Hz,3H).MS(ESI)m / z=436.3[M+H] + (C 26 H 33 N 3 O 3 ).
[0117] Example 13: Preparation of (R)-8-(Benzyloxy)-5-(2-(4-benzylpiperazin-1-yl)-1-hydroxyethyl)quinolin-2(1H)-one (I 13 )
[0118]
[0119] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and 1-benzylpiperazine (145 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 105 mg of the target product in a yield of 32.79%.
[0120] 1 H NMR (300MHz, DMSO-d6) δ10.58(s,1H),8.12(d,J=10.0Hz,1H),7.52(d,J=8.2Hz,2H),7.37-7.06(m,10H ),6.49(d,J=9.9Hz,1H),5.24(s,2H),5.08(m,1H),3.38(s,2H),2.57-2.46(m,2H),2.45-2.08(m,8H). 13C NMR (75MHz, DMSO) δ161.35,143.57,138.71,137.54,137.16,133.91,129.70,129.23,128.78,128.59,128.31,128 .25,127.32,122.17,119.91,117.35,112.54,70.21,67.50,66.35,62.54,53.70,53.10.MS(ESI)m / z=470.2[M+H] + (C 29 H 31 N 3 O 3 ).
[0121] Example 14: Preparation of (R)-8-(benzyloxy)-5-(1-hydroxy-2-(4-(4-methylbenzyl)piperazin-1-yl)ethyl)quinolin-2(1H)-one (I 14 )
[0122]
[0123] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and 1-(4-methylbenzyl)piperazine (156 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 125 mg of the target product in a yield of 37.91%.
[0124] 1 H NMR (300MHz, DMSO-d6) δ10.58(s,1H),8.12(d,J=10.0Hz,1H),7.52(d,J=6.8Hz,2H),7.30(m,3H),7.17 -6.99(m,6H),6.49(d,J=9.9Hz,1H),5.24(s,2H),5.07(m,1H),3.35(s,2H),2.39(m,10H),2.22(s,3H). 13 C NMR (75MHz, DMSO) δ161.35,143.57,137.54,137.16,136.30,135.59,133.92,129.70,129.22,129.15,128.78,128.31 ,128.25,122.16,119.90,117.35,112.52,70.21,67.53,66.36,62.29,53.71,53.07,21.16.MS(ESI)m / z=484.3[M+H]+ (C 30 H 33 N 3 O 3 )
[0125] Example 15: Preparation of (R)-8-(Benzyloxy)-5-(2-(4-(4-bromobenzyl)piperazin-1-yl)-1-hydroxyethyl)quinolin-2(1H)-one (I 15 )
[0126]
[0127] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and 1-(4-bromobenzyl)piperazine (209 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 133 mg of the target product with a yield of 35.56%.
[0128] 1 H NMR (400MHz, DMSO-d6) δ10.61(s,1H),8.17(d,J=9.9Hz,1H),7.57(d,J=7.5Hz,2 H),7.50(d,J=8.2Hz,2H),7.38(t,J=7.5Hz,2H),7.31(d,J=7.1Hz,1H),7.24(d,J =8.2Hz,2H),7.16(q,J=8.4Hz,2H),6.53(d,J=9.8Hz,1H),5.29(s,2H),5.15(s, 1H),5.11(s,1H),3.40(s,2H),2.60-2.52(m,2H),2.49-2.18(m,8H).MS(ESI)m / z 548.2[M+H] + (C 29 H 30 Bn 3 O 3 ).
[0129] Example 16: Preparation of (R)-8-(benzyloxy)-5-(2-(4-(4-fluorophenyl)piperazin-1-yl)-1-hydroxyethyl)quinolin-2(1H)-one (I 16 )
[0130]
[0131] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and 1-(4-fluorophenyl)piperazine (148 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 221 mg of the target product in a yield of 68.45%.
[0132] 1 H NMR (400 MHz, DMSO-d 6 )δ10.63(s,1H),8.23(d,J=9.9Hz,1H),7.58(d,J=7.4Hz,2H),7.38(t,J=7.4H z,2H),7.34–7.29(m,1H),7.19(s,2H),7.03(t,J=8.7Hz,2H),6.92(dd,J=9.1, 4.7Hz,2H),6.56(d,J=9.9Hz,1H),5.30(s,2H),5.20(dd,J=8.1,4.3Hz,1H),3 .04(t,J=5.1Hz,4H),2.64(qd,J=11.2,9.7,5.0Hz,5H),2.48(d,J=4.1Hz,1H). 13 CNMR (101MHz, DMSO-d 6 )δ161.37,143.64,137.58,137.17,133.87,129.76,128.80,128.33,128.27,122.22,119.99,1 17.52,117.44,117.38,115.79,115.58,112.58,70.26,67.70,66.14,53.61,49.42.MS(ESI)m / z 474.3[M+H] + (C 28 H 28 FN 3 O 3 ).
[0133] Example 17: Preparation of (R)-8-(Benzyloxy)-5-(2-(4-benzyl-1,4-diazepin-1-yl)-1-hydroxyethyl)quinolin-2(1H)-one (I 17 )
[0134]
[0135] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and 1-benzylhomopiperazine (130 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 101 mg of the target product in a yield of 30.63%.
[0136] 1 H NMR (300MHz, DMSO-d6) δ10.60(s,1H),8.15(d,J=10.0Hz,1H),7.52(d,J=8.2Hz,2H),7.36-7.26(m,3H),7.24(m,5H),7.12(d,J=4.0 Hz,2H),6.49(d,J=9.9Hz,1H),5.24(s,2H),5.02(t,J=6.2Hz,1H),3.50(s,2H),2.79-2.60(m,6H),2.55-2.48(m,3H),1.59(m,2H). 13 C NMR (75MHz, DMSO) δ160.77,142.95,139.35,136.97,136.58,133.22,129.10,128.34,128.19,127.99,127.71,127.65,126.6 0,121.55,119.45,116.87,111.98,69.63,67.57,65.09,61.58,54.91,54.57,54.03,53.64,27.21.MS(ESI)m / z=484.3[M+H] + (C 30 H 33 N 3 O 3 ).
[0137] Example 18: Preparation of (R)-8-(benzyloxy)-5-(1-hydroxy-2-(4-(4-methylbenzyl)-1,4-diazepin-1-yl)ethyl)quinolin-2(1H)-one (I 18 )
[0138]
[0139] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and 1-(4-methylbenzyl)homopiperazine (167 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 98 mg of the target product in a yield of 28.88%.
[0140] 1 H NMR (300MHz, DMSO-d6) δ10.59(s,1H),8.16(d,J=10.0Hz,1H),7.53(d,J=6.8Hz,2H),7.31(m,3H),7.16-7.04(m,6H),6.50( d,J=9.9Hz,1H),5.26(s,2H),5.02(t,J=6.3Hz,1H),3.46(s,2H),2.76-2.60(m,6H),2.52(m,4H),2.23(s,3H),1.61(m,2H). 13 CNMR(75MHz,DMSO)δ161.35,143.53,137.57,137.17,136.79,136.16,133.83,129.69,129.16,128.93,128.78,128.31,128.24, 122.14,120.03,117.45,112.56,70.22,68.16,65.68,61.92,55.51,55.07,54.60,54.17,27.81,21.16.MS(ESI)m / z=498.3[M+H] + (C 31 H 35 N 3 O 3 )
[0141] Example 19: Preparation of (R)-8-(Benzyloxy)-5-(1-hydroxy-2-morpholinoethyl)quinolin-2(1H)-one (I 19 )
[0142]
[0143] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and morpholine (72 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 63 mg of the target product in a yield of 24.29%.
[0144] 1H NMR (400MHz, DMSO-d6) δ10.62(s,1H),8.19(d,J=11.7Hz,1H),7.57(d,J=7.2Hz,2H),7.42-7.35(m,2H),7.32(d,J=7. 6Hz,1H),7.25-7.13(m,2H),6.55(d,J=9.9Hz,1H),5.29(s,2H),5.15(s,1H),3.53(s,4H),2.56(m,2H),2.42(m,4H). 13 C NMR (101MHz, DMSO) δ161.34,143.59,137.53,137.16,133.84,129.73,128.79,128.34,128.26 ,122.21,119.95,117.33,112.56,70.24,67.46,66.72,66.69,54.23.MS(ESI)m / z=381.2[M+H] + (C 22 H 24 N 2 O 4 ).
[0145] Example 20: Preparation of (R)-8-(Benzyloxy)-5-(1-hydroxy-2-(piperidin-1-yl)ethyl)quinolin-2(1H)-one (I 20 )
[0146]
[0147] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and piperidine (70 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 87 mg of the target product in a yield of 33.71%.
[0148] 1 H NMR (400MHz, DMSO-d6) δ10.63(s,1H),8.19(d,J=9.9Hz,1H),7.57(d,J=7.0Hz,2H),7.38(t,J=7.2Hz,2H),7.31(t,J=7.3Hz,1H),7 .24-7.12(m,2H),6.54(d,J=9.9Hz,1H),5.29(s,2H),5.16(s,1H),2.56(m,2H),2.42(s,4H),1.53-1.43(m,4H),1.39-1.33(m,2H). 13C NMR (101MHz, DMSO) δ161.35,143.60,137.51,137.16,133.74,129.69,128.79,128.32,128.25 ,122.17,119.87,117.33,112.56,70.22,67.14,54.82,25.78,24.19.MS(ESI)m / z=379.2[M+H] + (C 23 H 26 N 2 O 3 ).
[0149] Example 21: Preparation of (R)-8-(Benzyloxy)-5-(1-hydroxy-2-(pyrrolidin-1-yl)ethyl)quinolin-2(1H)-one (I 21 )
[0150]
[0151] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and tetrahydropyrrole (58 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 85 mg of the target product with a yield of 34.21%.
[0152] 1 H NMR (400MHz, DMSO-d6) δ10.63 (s, 1H), 8.21 (d, J = 10.0 Hz, 1H), 7.57 (d, J = 8. 3Hz,2H),7.37(t,J=7.3Hz,2H),7.31(t,J=7.3Hz,1H),7.16(q,J=8.4Hz,2H) ,6.54(d,J=9.9Hz,1H),5.29(s,2H),5.11-5.04(m,1H),2.73(dd,J=12.5,8 .0Hz,1H),2.62(dd,J=12.5,4.6Hz,1H),2.55(d,J=6.5Hz,4H),1.65(s,4H). 13 C NMR (101MHz, DMSO) δ161.33,143.67,137.43,137.16,133.59,129.78,128.80,128.32,128.25 ,122.28,120.08,117.37,112.49,70.21,68.83,63.83,54.47,23.57.MS(ESI)m / z=365.2[M+H] + (C22 H 24 N 2 O 3 ).
[0153] Example 22: Preparation of (R)-8-(benzyloxy)-5-(1-hydroxy 2-(phenylamino)ethyl)-1-hydroxyethyl)quinolin-2(1H)-one (I 22 )
[0154]
[0155] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and aniline (76 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 60 mg of the target product in a yield of 22.77%.
[0156] 1 H NMR (400 MHz, DMSO-d 6 )δ10.60(s,1H),8.35(d,J=10.0Hz,1H),7.57(dt,J=6.2,1.4Hz,2H),7.38(t,J =7.3Hz,2H),7.31(t,J=7.3Hz,1H),7.15(s,2H),6.96(t,J=7.8Hz,2H),6.62(d, J=9.9Hz,1H),6.47(d,J=6.4Hz,2H),6.46(d,J=1.2Hz,1H),6.05(d,J=6.1Hz,1H ),5.25(s,2H),4.97(t,J=5.9Hz,1H),4.89(q,J=6.4Hz,1H),3.68–3.55(m,2H). 13 C NMR (101 MHz, DMSO-d 6 )δ161.33,148.33,143.66,137.19,136.66,130.85,129.79,129.21,128.81,128.35,128.32,1 22.62,120.09,118.11,116.33,113.17,112.64,70.26,66.05,55.62.MS(ESI)m / z=387.2[M+H] + (C 24 H 22 N 2 O 3 ).
[0157] Example 23: Preparation of (R)-8-(benzyloxy)-5-(2-((2-bromophenyl)amino)-1-hydroxyethyl)quinolin-2(1H)-one (I 23 )
[0158]
[0159] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and 2-bromoaniline (141 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 85 mg of the target product in a yield of 26.79%.
[0160] 1 H NMR (400MHz, DMSO-d6) δ10.68(s,1H,NH),8.35(d,J=10.0Hz,1H),7.56(d,J=6.4H z,2H),7.42(d,J=7.9Hz,1H),7.39-7.35(d,J=8.4Hz,1H),7.31(d,J=6.0Hz,1H), 7.16(d,J=8.4Hz,1H),6.98(m,2H),6.63(d,J=9.8Hz,1H),6.49(t,J=7.6Hz,1H), 6.25(d,J=8.2Hz,1H),5.24(s,2H),5.03(s,1H),3.79(m,1H),3.68-3.49(m,1H). 13 C NMR (101MHz, DMSO) δ161.29,144.36,143.90,143.87,137.09,136.29,132.61,129.98,129.23,128.97,128.80, 128.35,122.90,119.88,118.35,117.70,113.24,112.60,109.68,70.23,65.40,55.31.MS(ESI)m / z=465.1[M+H] + (C 24 H 21 Bn 2 O 3 ).
[0161] Example 24: Preparation of (R)-8-(benzyloxy)-5-(1-hydroxy-2-(isobutylamino)ethyl)quinolin-2(1H)-one (I 24 )
[0162]
[0163] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and isobutylamine (123 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 73 mg of the target product in a yield of 29.22%.
[0164] 1 H NMR (400 MHz, DMSO-d 6 )δ8.23(d,J=10.0Hz,1H),7.57(d,J=7.1Hz,2H),7.38(t,J=7.3Hz,2H),7.31(t,J=7.3Hz,1H),7.21–7.15(m,2H),6.56(d,J=9.8Hz,1H),5. 30(s,2H),5.18–5.13(m,1H),2.76(s,1H),2.74(s,1H),2.45(dd,J=6.8,1.9Hz,2H),1.72(hept,J=6.7Hz,1H),0.87(dd,J=6.7,4.1Hz,6H). 13 C NMR (101 MHz, DMSO-d 6 )δ161.31,143.74,137.16,128.82,128.77,128.27,128.22,119.88,112.57,70.22,68.21,56.89,27.76,20.95.MS(ESI)m / z=367.2[M+H] + (C 22 H 26 N 2 O 3 ).
[0165] Example 25: Preparation of (R)-8-(benzyloxy)-5-(2-(3,4-dihydroisoquinolin-2(1H)-yl)-1-hydroxyethyl)quinolin-2(1H)-one (I 25 )
[0166]
[0167] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and (S)-2,3-dihydro-1H-indan-1-amine (109 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 112 mg of the target product in a yield of 38.51%.
[0168] 1 H NMR (300MHz, DMSO-d6) δ10.67(s,1H),8.18(d,J=9.9Hz,1H),7.58(d,J=7.4Hz,2H ),7.39(t,J=7.3Hz,2H),7.33(d,J=7.1Hz,1H),7.28(d,J=7.6Hz,1H),7.23-7.12( m,5H),6.54(d,J=9.9Hz,1H),5.30(s,2H),5.05(d,J=5.0Hz,1H),4.19(t,J=6.6Hz ,1H),2.98-2.62(m,5H),2.27(m,1H),1.78-1.66(m,1H).MS(ESI)m / z=427.2[M+H] + (C 27 H 26 N 2 O 3 ).
[0169] Example 26: Preparation of (R)-8-(Benzyloxy)-5-(1-hydroxy-2-(indol-1-yl)ethyl)quinolin-2(1H)-one (I 26 )
[0170]
[0171] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and indoline (98 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 103 mg of the target product in a yield of 36.62%.
[0172] 1H NMR (300MHz, DMSO-d6) δ10.64(s,1H),8.04(d,J=9.9Hz,1H),7.58(d,J=7.3Hz,2H),7.37(m,3H),7.1 8(s,2H),6.97(d,J=6.2Hz,1H),6.89(t,J=7.6Hz,1H),6.56(d,J=9.9Hz,1H),6.47(t,J=7.2Hz,1H),6 .33(d,J=7.6Hz,1H),5.29(s,2H),4.97(t,J=5.6Hz,1H),4.88(s,1H),3.90(dt,J=11.4,5.4Hz,2H), 3.52(q,J=9.5,8.9Hz,1H),3.28-3.21(m,1H),2.85(dt,J=17.1,8.0Hz,2H).MS(ESI)m / z=413.2[M+H] + (C 26 H 24 N 2 O 3 ).
[0173] Example 27: Preparation of (R)-8-(benzyloxy)-5-(1-hydroxy-2-((1-(methylsulfonyl)piperidin-4-yl)amino)ethyl)quinolin-2(1H)-one (I 27 )
[0174]
[0175] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and 1-methanesulfonyl-4-aminopiperidine (146 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 52 mg of the target product in a yield of 16.17%.
[0176] 1 H NMR (400 MHz, DMSO-d 6 ) 1 H NMR (400 MHz, DMSO-d 6)δ10.66(s,1H),8.31(s,1H),8.22(d,J=9.9Hz,1H),7.57(d,J=6.9Hz,2H), 7.38(t,J=7.3Hz,2H),7.34–7.29(m,1H),7.23–7.16(m,2H),6.57(d,J=9.9 Hz,1H),5.31(s,2H),5.13(dd,J=7.7,4.7Hz,1H),3.47(dd,J=11.8,4.6Hz, 2H),2.84(s,5H),2.79–2.70(m,3H),1.97–1.89(m,2H),1.46–1.35(m,2H). 13 C NMR (101 MHz, DMSO-d 6 )δ165.37,161.34,143.81,137.19,137.15,132.81,129.82,128.82,128.35,128.26,122.50,119.9 3,117.27,112.57,70.21,68.42,53.61,53.45,44.44,34.66,30.62,30.41.MS(ESI)m / z=472.2[M+H] + (C 24 H 29 N 3 O 5 S).
[0177] Example 28: Preparation of (R)-8-(Benzyloxy)-5-(2-(Benzo[d]thiazol-5-ylamino)-1-hydroxyethyl)quinolin-2(1H)-one (I 28 )
[0178]
[0179] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and 1,3-benzothiazole-5-amine (123 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 84 mg of the target product with a yield of 27.78%.
[0180] 1 H NMR (400 MHz, DMSO-d 6)δ10.60(s,1H),10.10(s,1H),9.12(s,1H),8.43(d,J=9.9Hz,1H),7.72(d,J=8.6Hz ,1H),7.56(d,J=7.5Hz,2H),7.37(t,J=7.5Hz,2H),7.32(s,1H),7.16(d,J=4.9Hz,2H ),6.93(d,J=8.6Hz,1H),6.87(s,1H),6.64(d,J=9.6Hz,1H),5.23(s,2H),4.99(t,J =5.9Hz,1H),3.70(d,J=10.7Hz,1H),3.66(d,J=6.9Hz,1H).MS(ESI)m / z=444.1[M+H] + (C 25 H 21 N 3 O 3 S).
[0181] Example 29: Preparation of (R)-8-(Benzyloxy)-5-(2-((1H-benzo[d]imidazol-2-yl)amino)-1-hydroxyethyl)quinolin-2(1H)-one (I 2 )
[0182]
[0183] Referring to the method of step 1.4 in Example 1, the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200 mg, 0.68 mmol) and 2-aminobenzimidazole (109 mg, 0.82 mmol) were reacted and purified by silica gel column chromatography to obtain 68 mg of the target product in a yield of 23.38%.
[0184] 1 H NMR (400 MHz, DMSO-d 6 )δ10.70(s,1H),8.26(s,1H),7.56(d,J=7.3Hz,2H),7.38(t,J=7.3Hz,2H),7 .32(d,J=7.2Hz,1H),7.25–7.16(m,2H),7.15–7.09(m,2H),6.91(dd,J=6.0, 3.2Hz,2H),6.82(d,J=8.2Hz,1H),6.54(d,J=9.9Hz,1H),5.34(d,J=3.6Hz,1 H),5.30(s,2H),4.25(dd,J=15.0,8.1Hz,1H),4.15(dd,J=14.9,4.1Hz,1H). 13C NMR (101 MHz, DMSO-d 6 )δ165.06,161.32,155.49,144.05,141.84,137.60,137.11,137.08,134.92,131.72,129.88,128.81,128.33,128.21,122. 54,120.86,120.65,120.10,118.82,117.62,114.87,112.58,111.88,108.50,70.21,68.77,49.41.MS(ESI)m / z=427.2[M+H] + (C 25 H 22 N 4 O 3 ).
[0185] Example 30: Preparation of (R)-8-(benzyloxy)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-fluoroethyl)quinolin-2(1H)-one (I' 1 )
[0186]
[0187] The indacaterol intermediate (R)-8-benzyloxy-5-(-2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)quinolin-2(1H)-one, LYW1 (100 mg) was dissolved in dichloromethane (5 mL), and the temperature was lowered to about -20°C after nitrogen replacement. After stirring for 10 min, the fluorination reagent DAST (41 mg, 0.25 mmol) was slowly added dropwise, and the temperature was maintained and stirred until the reaction was complete. After the reaction was completed, a saturated sodium bicarbonate solution was added to quench the DAST, and the organic layers were combined after dichloromethane extraction, concentrated, and purified by silica gel column chromatography to obtain 60 mg of the target compound with a yield of about 59.75%.
[0188] 1 H NMR (300 MHz, DMSO-d 6)δ8.13(d,J=9.9Hz,1H),7.63–7.59(m,2H),7.45–7.38(m,3H),7.25(s,1H),7.2 0(d,J=8.5Hz,1H),6.99–6.95(m,2H),6.62(d,J=9.9Hz,1H),5.35(s,2H),3.59( p,J=6.7,6.2Hz,1H),3.26–3.16(m,1H),3.02(dt,J=15.5,6.4Hz,3H),2.69–2.6 2(m,2H),2.59(d,J=7.7Hz,4H),1.13(d,J=7.5Hz,6H).MS(ESI)m / z=485.3[M+H] + (C 31 H 33 FN 2 O 2 ).
[0189] Example 31: Preparation of (S)-8-(benzyloxy)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-fluoroethyl)quinolin-2(1H)-one (I' 2 )
[0190]
[0191] The enantiomer of LYW1 (S)-8-benzyloxy-5-(-2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)quinolin-2(1H)-one (100 mg) was dissolved in dichloromethane (5 ml), and the temperature was lowered to about -20°C after nitrogen replacement. After stirring for 10 min, the fluorination reagent DAST (41 mg, 0.25 mmol) was slowly added dropwise, and the temperature was maintained and stirred until the reaction was complete. After the reaction, a saturated sodium bicarbonate solution was added to quench the DAST, and the organic layers were combined after extraction with dichloromethane, concentrated, and purified by silica gel column chromatography to obtain 63 mg of the target compound with a yield of about 62.74%.
[0192] 1 H NMR (300 MHz, DMSO-d 6)δ8.14(d,J=9.9Hz,1H),7.62(d,J=6.9Hz,2H),7.43(t,J=7.1Hz,3H),7.28 (d,J=8.4Hz,1H),7.22(d,J=8.4Hz,1H),6.99(d,J=1.7Hz,2H),6.64(d,J=9 .9Hz,1H),5.37(s,2H),3.68–3.62(m,1H),3.11–2.99(m,3H),2.79–2.65(m ,3H),2.61(d,J=7.5Hz,4H),1.17(d,J=7.5Hz,6H).MS(ESI)m / z=485.3[M+H] + (C 31 H 33 FN 2 O 2 ).
[0193] II. Inhibitory effect of compound I on colorectal cancer cell lines
[0194] Based on the therapeutic effect of indacaterol, we screened its intermediate LYW1 as the lead compound and studied the in vitro inhibitory effect of series compound I on colorectal cancer cell lines. It was found that it had a strong inhibitory effect on RKO, HT29, and SW620. The specific experimental process and results are as follows:
[0195]
[0196] 1. Inhibitory effect of compound I on SW620 cells:
[0197] Indacaterol was used as a positive control and a concentration gradient of 10, 20, 30, and 40 μM was prepared. The IC 50 Fixed between 20-25 μM. Compound I was prepared in the same concentration gradient for primary screening and had a lower IC than indacaterol 50 The compounds were screened for the second time, and the concentration gradient of the compounds was 1, 2, 4, and 8 μM.
[0198] Both rounds of screening were performed on the colorectal cancer cell line SW620. The initial number of cells was 5000 per well. The cell viability at 48 h was directly measured to determine the IC of the compound. 50 .
[0199] Cell viability = [(experimental group reading - blank group reading) / (control group reading - blank group reading)] × 100%.
[0200] Table 1 Inhibitory effect of compound I on SW620
[0201] Compound <![CDATA[IC 50 (μM)]]> Compound <![CDATA[IC 50 (μM)]]> Indacaterol 23.05 <![CDATA[I 11 ]]> 6.093 LYW1 3.542 <![CDATA[I 13 ]]> 36.31 <![CDATA[I 1 (LYW2)]]> 3.121 <![CDATA[I 14 ]]> 22.33 <![CDATA[I 2 ]]> 8.624 <![CDATA[I 15 ]]> 11.02 <![CDATA[I 4 ]]> 2.899 <![CDATA[I 17 ]]> 22.22 <![CDATA[I 5 (WHEEL3)]]> 2.975 <![CDATA[I 18 ]]> 19.35 <![CDATA[I 6 ]]> 3.055 <![CDATA[I 23 ]]> 25.61 <![CDATA[I 7 (STEER4)]]> 2.734 <![CDATA[I 25 ]]> 24.76 <![CDATA[I 9 ]]> 3.154 <![CDATA[I 26 ]]> 20.34 <![CDATA[I 10 ]]> 4.184
[0202] 2. Inhibitory effect of compound I on RKO (human colon adenocarcinoma cells) and HT29 (human colon cancer cells):
[0203] Indacaterol was used as a positive control and its IC 50 The concentration was fixed at 10-15 μM, and the other procedures were the same as those for the SW620 cell line.
[0204] Table 2 Inhibitory effects of compounds on RKO
[0205] Compound <![CDATA[IC 50 (μM)]]> Indacaterol 12.79 LYW1 2.033 <![CDATA[I 1 (LYW2)]]> 1.422 <![CDATA[I 2 ]]> 5.563 <![CDATA[I 7 (STEER4)]]> 3.107
[0206] Table 3 Inhibitory effects of compounds on HT29
[0207] Compound <![CDATA[IC 50 (μM) <!-- 28 -->]]> Indacaterol 12.71 LYW1 2.425 <![CDATA[I 1 (LYW2)]]> 1.422 <![CDATA[I 2 ]]> 4.687 <![CDATA[I 7 (STEER4)]]> 2.663
[0208] 3. Study on the binding effect of compound I1 and SRSF6 protein
[0209] SRSF proteins play an important role in gene expression regulation processes such as constitutive splicing of mRNA precursors, alternative splicing, mRNA nuclear export, and translation. SRSF proteins are divided into two groups according to the number of RRM domains they contain, among which SRSF6 has two domains, RRM1 and RRM2. The RRM1 domain contains RNP-1 and RNP-2 conserved sequences, which can bind to related RNAs; while the RRM2 domain contains the evolutionarily conserved SWQDLKD heptapeptide sequence. In the specific recognition of alternative splicing sites, the RRM1 and RRM2 domains play an irreplaceable role. Overexpressed SRSF6 binds to the cell adhesion factor ZO-1 and induces the occurrence of colorectal cancer, and indacaterol has been proven to inhibit the occurrence and development of tumors. Therefore, we extracted the RRM1 and RRM2 domain fragments of SRSF6 protein and confirmed the significant binding of indacaterol and its intermediate (LYW1) to SRSF6 by surface plasmon resonance (SPR) experiment. Then, we used LYW1 as a reference and investigated the binding of compound I to SRSF6 by protein thermal shift experiment. 1 (LYW2) binding ability to SRSF6 protein.
[0210] We used DMSO as a blank group, added 56.5 μM SRSF6 protein to LYW1 and LYW2 at a concentration of 1:10 in a PCR tube, and then added TS dye in a dark environment to perform a thermal migration experiment. The experimental results are as follows:
[0211] Table 4 Results of thermal migration experiment of SRSF6 protein
[0212] # Well Protein Ligand Task ΔTm B ΔTm D 1 A01 SRSF6 DMSO R 0.01 -0.07 2 B01 SRSF6 DMSO R -0.01 0.07 3 C01 SRSF6 LYW1 S -14.11 -13.66 4 D01 SRSF6 LYW1 S -13.12 -12.82 5 E01 SRSF6 LYW2 S -10.35 -10.16 6 F01 SRSF6 LYW2 S -11.58 -10.86
[0213] The experimental results show that LYW1, I 1 (LYW2) Compared with DMSO, both compounds caused negative migration of SRSF6 protein to varying degrees, but LYW1 itself has strong fluorescence, so I 1 (LYW2) has a better binding effect with SRSF6 protein ( Figure 1 ).
[0214] 4. I 1 ,I 5 ,I 7 In vivo pharmacokinetic studies in rats
[0215] In order to study the structure-activity relationship and drugability of the series of compounds I of the present invention, we investigated the pharmacokinetic characteristics and oral absolute bioavailability of the series of compounds in rats after administration, providing pharmacokinetic data support for subsequent studies on the in vivo efficacy of candidate compounds. We used LYW1 as a control and selected compound I with better results in the cell activity experiment. 1 (LYW2), I 5 (LYW3), I 7 (LYW4) was administered to rats (n=3) by intravenous injection of 5 mg / kg and oral gavage of 100 mg / kg. Plasma was collected at a given time. HPLC-MS / MS methods were established to determine the concentration of the compound in rat plasma. The pharmacokinetic parameters were calculated using WinNonlin software. The data results are as follows:
[0216] LYW1: After intravenous administration of LYW1 (5 mg / kg), AUC 0-t 626.82±17.46h·μg / L, AUC 0-∞ 646.42±19.69h·μg / L, t 1 / 2 The AUC of LYW1 was about 4.07±0.74h, the apparent distribution volume V was about 45.58±9.55L / kg, and the clearance rate CL was about 7.74±0.24L / h / kg. After oral administration of LYW1 (100mg / kg), AUC 0-t 323.75±78.04h·μg / L, AUC 0-∞ The peak concentration was 352.78±72.78h·μg / L, and the peak concentration was C max The value was 212.58±45.86μg / L, and the peak time was T max The oral absolute bioavailability is 2.73% ( Figure 2 LYW2: After intravenous administration of LYW2 (5 mg / kg), AUC0-t 1986.59±312.69h·μg / L, AUC 0-∞ 2117.28±322.75h·μg / L, t 1 / 2 The average release time was about 6.02±0.37h, the apparent distribution volume V was about 20.88±3.84L / kg, and the clearance rate CL was about 2.40±0.35L / h / kg. After oral administration of LYW2 (100mg / kg), AUC 0-t 5223.36±395.51h·μg / L, AUC 0-∞ The peak concentration was 5287.25±386.25h·μg / L, and the peak concentration was C max The value was 357.75±43.49μg / L, and the peak time was T max The oral absolute bioavailability was 9.33±2.31h and 12.49% ( Figure 2 (as shown in Figure B).
[0217] LYW3: After intravenous administration of LYW3 (5 mg / kg), AUC 0-t 859.95±11.40h·μg / L, AUC 0-∞ 875.48±11.30h·μg / L, t 1 / 2 The AUC of LYW3 was about 3.94±0.09h, the apparent distribution volume V was about 32.47±0.64L / kg, and the clearance CL was about 5.71±0.07L / h / kg. After oral administration of LYW3 (100mg / kg), AUC 0-t 3168.54±280.72h·μg / L, AUC 0-∞ The peak concentration was 3195.56±250.81h·μg / L, and the peak concentration was C max The value was 277.72±48.87μg / L, and the peak time was T max The oral absolute bioavailability is 18.25% ( Figure 2 (as shown in Figure C).
[0218] LYW4: After intravenous administration of LYW4 (5 mg / kg), AUC 0-t 1172.54±19.18h·μg / L, AUC 0-∞ 1194.06±21.48h·μg / L, t 1 / 2 The AUC of LYW4 was about 4.10±0.34h, the apparent distribution volume V was about 24.75±1.92L / kg, and the clearance CL was about 4.19±0.07L / h / kg. After oral administration of LYW4 (100mg / kg), AUC 0-t4856.18±370.32h·μg / L, AUC 0-∞ The peak concentration was 4896.71±363.75h·μg / L, and the peak concentration was C max The value was 188.21±27.61μg / L, and the peak time was T max The oral absolute bioavailability was 20.50% ( Figure 2 (as shown in Figure D).
[0219] According to the data results and Figure 2 As shown, intravenous injection (5 mg / kg) and oral administration (100 mg / kg) ( Figure 2 E Figure and Figure 2 The plasma drug concentrations were all low after intravenous injection of LYW1, LYW2, LYW3, and LYW4. 2min The concentrations of the compounds in the rats were 604.18±61.50, 979.86±162.90, 601.66±40.37, and 722.16±60.39 μg / L, respectively. The compounds may be rapidly distributed after entering the body, and the apparent distribution volume is large, which may indicate that the compounds are widely distributed or have specific tissue distribution. After oral administration, compared with the control, the absorption rate of the series of compounds in rats is slow, while the control LYW1 is rapidly absorbed. max The value is 0.14±0.05h, while the rest of T max The values were 9.33±2.31, 6.00±0.00, and 16.00±6.93h, respectively. The oral bioavailability of the series of compounds was significantly improved compared with that of the control. After intravenous injection, the blood concentration data of LYW2-6h showed that the metabolism of LYW2, LYW3, and LYW4 slowed down, while the control did not have this phenomenon. It is speculated that the series of compounds may have biliary excretion and enterohepatic circulation.
[0220] The above data show that the series of compounds of the present invention have better pharmacokinetic parameters.
[0221] In summary, based on the inhibitory effect of indacaterol on colorectal cancer, we screened the lead compound LYW-1 and optimized its structure to synthesize a new series of compounds I. In vitro studies have found that it can significantly inhibit the occurrence and development of colorectal cancer cells induced by SRSF6 overexpression; the results of in vivo pharmacokinetic experiments further prove that this series of compounds is superior to the in vivo drug metabolism data of the lead compound LYW-1, providing data support for subsequent efficacy and toxicology studies, and providing the possibility for the development of small molecule anti-tumor drugs with SRSF6 as a new target, which has good application prospects.
Claims
1. A small molecule compound targeting SRSF6 protein, characterized in that: The compound structural formula is:
2. The method for preparing the compound according to claim 1, characterized in that: The following steps are involved: 5-Acetyl-2,8-dihydroxyquinoline and R 1 X is reacted and then brominated to obtain compound II, wherein the brominating agent selected for bromination is selected from bromine water, N-bromosuccinimide or tetrabutylammonium tribromide; compound II is stereoselectively reduced to compound III by (R) / (S)-2-methyl-CBS-oxazolidinone coordinated with borane, and compound III is intramolecularly cyclized under alkaline conditions and then reacts with a nucleophilic reagent R 2 H reaction to obtain the target compound I, the synthesis route is as follows: Among them, R 1 , R 2 and chiral configurations respectively correspond to the specific compounds of claim 1.
3. The method for preparing the compound according to claim 2, characterized in that: In the reaction of preparing compound III from compound II: the solvent is selected from one or more of acetonitrile, dichloromethane, chloroform, tetrahydrofuran, N,N′-dimethylformamide, and dimethyl sulfoxide; the reaction temperature is -20°C to 25°C; In the reaction of preparing compound IV from compound III: the solvent is selected from one or more of acetonitrile, dichloromethane, chloroform, acetone, tetrahydrofuran, methanol, N,N-dimethylformamide, dimethyl sulfoxide or dioxane; the base is selected from potassium carbonate, sodium carbonate, sodium bicarbonate, sodium hydroxide, potassium hydroxide or triethylamine; the reaction temperature is from 25°C to heating reflux; In the reaction of preparing compound I from compound IV: the solvent is selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, n-butanol or diethylene glycol dimethyl ether; and the reaction temperature is 60°C to 150°C.
4. The method for preparing the compound according to claim 3, characterized in that: In the reaction of preparing compound III from compound II: the solvent is anhydrous tetrahydrofuran, and the reaction temperature is -20°C to 0°C; In the reaction of preparing compound IV from compound III: the solvent is acetone, the base is potassium carbonate or triethylamine, and the reaction temperature is 55°C to 65°C; In the reaction of preparing compound I from compound IV: the solvent is selected as n-butanol, and the reaction temperature is 110°C to 120°C.
5. Use of the compound according to claim 1 in the preparation of drugs for treating diseases related to malignant tumors.
6. The use according to claim 5, characterized in that The malignant tumor-related diseases are tumors mediated by overexpression of SRSF6 protein, including colorectal tumors.
Citation Information
Patent Citations
Application of indacaterol in treatment of colorectal cancer
CN107582550A
Application of indacaterol maleate to preparation of tumor resisting medicines
CN110013481A
Betz 2-adrenoceptor agonists
CN1353692A
Quinoline-2-one-derivatives for the treatment of airways diseases
CN1798559A
